SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Septerna, a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced that members of the management team, including Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder, and Liz Bhatt, MS, MBA, Chief Operating Officer, will participate in the following investor and industry conferences:
Evercore ISI 2024 Emerging Private Biotech Conference
Presentation: Wednesday, February 28, 2024, at 2:50 p.m. ET.
Location: Virtual.
TD Cowen 44th Annual Health Care Conference
Participation: Monday, March 4, 2024.
Location: Boston, MA.
Fierce Biotech 2024 Business Development and Licensing Summit
Panel: “Dynamics and Structures for Negotiating and Evaluating Platform Deals” on Monday, March 11, 2024, at 1:15 p.m. PT.
Location: San Francisco, CA.
Leerink Partners 2024 Global Biopharma Conference
Participation: Wednesday, March 13, 2024.
Location: Miami, FL.
About Septerna
Septerna, Inc. is a biotechnology company focused on advancing novel, oral small molecule medicines targeting the entire class of G protein-coupled receptors (GPCRs). The company’s Native Complex Platform™ recapitulates GPCRs with their native structure, function, and dynamics outside of the cellular environment to rapidly apply new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. Septerna was launched in 2022 by scientific founders who have made groundbreaking GPCR discoveries. For more information, please visit www.septerna.com.
